ANN ARBOR—Esperion Therapeutics Inc. has finally launched the cholesterol busting drug the company has been development and made Nexlizet tablets available in the United States. Nexlizet is a combination of bempedoic acid and ezetimibe. Bempedoic acid is the Esperion-developed active ingredient in Nexletol tablets, approved by the U.S. Food and Drug Administration and introduced earlier
ANN ARBOR—Esperion Therapeutics Inc. has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a “positive opinion” for both its bempedoic acid and its benpedoic acid-ezetimibe tablets to treat high cholesterol and other risky conditions involving lipids in the bloodstream. Company officials said the committee “found there were no
ANN ARBOR - Enzo Life Sciences has released its newest immunohistochemistry product, MULTIVIEW® PLUS (mouse-HRP/rabbit-AP) IHC Kit (Brown/Green). This non-biotin nanopolymer detection system contains reagents and materials that detect and localize antigens in formalin-fixed paraffin-embedded tissues. The new MULTIVIEW PLUS IHC kit optimizes your IHC process by including the entire workflow, from antigen retrieval to
ANN ARBOR - RetroSense Therapeutics, a privately-held biopharmaceutical company, announced Monday the first patient has been successfully dosed in the first clinical trial to evaluate the safety of of a drug to restore some vision for people suffering from Retinitis Pigmentosa, which can result in vision loss and blindness. “Successfully dosing our first patient with
